Interleukin Inhibitors

Name
Interleukin Inhibitors
Accession Number
DBCAT002105
Description

Not Available

ATC Classification
Drugs
DrugDrug Description
AnakinraA recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease.
BasiliximabA monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.
DaclizumabA monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
BriakinumabInvestigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis.
UstekinumabA targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.
CanakinumabAn interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).
TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
RilonaceptAn IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder.
SecukinumabAn immunomodulating agent and interleukin antagonist used to manage moderate to severe plaque psoriasis and active psoriatic arthritis or ankylosing spondylitis.
SiltuximabAn interleukin antagonist used to treat multicentric Castleman's disease (MCD) in patients who are HIV and HHV-8 negative.
BrodalumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
IxekizumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
SarilumabA monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs.
SirukumabSirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
GuselkumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
TildrakizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
RisankizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
Drugs & Drug Targets
DrugTargetType
AnakinraInterleukin-1 receptor type 1target
BasiliximabInterleukin-2 receptor subunit alphatarget
BasiliximabInterleukin-2 receptor subunit betatarget
DaclizumabInterleukin-2 receptor subunit alphatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DaclizumabComplement C1r subcomponenttarget
DaclizumabComplement C1q subcomponent subunit Atarget
DaclizumabComplement C1q subcomponent subunit Btarget
DaclizumabComplement C1q subcomponent subunit Ctarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DaclizumabInterleukin-2 receptor subunit betatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BriakinumabInterleukin-12 subunit betatarget
BriakinumabInterleukin-23 subunit alphatarget
UstekinumabInterleukin-12 subunit betatarget
UstekinumabInterleukin-23target
CanakinumabInterleukin-1 betatarget
TocilizumabInterleukin-6 receptor subunit alphatarget
TocilizumabCytochrome P450 3A4enzyme
RilonaceptInterleukin-1 betatarget
RilonaceptInterleukin-1 alphatarget
RilonaceptInterleukin-1 receptor antagonist proteintarget
SecukinumabInterleukin-17Atarget
SiltuximabInterleukin-6target
SiltuximabCytochrome P450 3A4enzyme
IxekizumabInterleukin-17Atarget
SarilumabCytochrome P450 3A4enzyme
SarilumabInterleukin-6 receptor subunit alphatarget
SarilumabHigh affinity immunoglobulin gamma Fc receptor Itarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
GuselkumabInterleukin-23 subunit alphatarget
TildrakizumabInterleukin-23target
TildrakizumabCytochrome P450 4A11enzyme
RisankizumabInterleukin-23target